Add PNH to Your Hypercoagulation Panel in Patients with Unexplained Thrombosis

Venous thromboembolism (VTE) is 62x more likely to occur in PNH versus 2x to 8x more likely for other hypercoagulable states 1

  • Venous or arterial thromboses account for approximately 40% to 67% of PNH-related deaths4
  • First thrombotic event (TE) increases risk for death 5- to 10-fold4
  • Incidence of first-ever ischemic stroke (FEIS) is elevated in PNH patients; age of FEIS in the PNH population (median age 46) is markedly lower than the general population (median age 72)4,6

Patients with PNH have a higher relative risk of developing a VTE than other hypercoagulable states.1,2







IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established. Therefore, treatment with Soliris should not alter anticoagulant management.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, and fatigue.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

References: 1. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;87:1095-1108. 2. Hill A, Platts PJ, Smith A, et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire [ASH abstract]. Blood. 2006;108: Abstract 985. 3. De Stefano V, Rossi E, Za T, Leone G. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. Semin Thromb Hemost. 2006;32:767-780. 4. Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123-4128. 5. Data on file, Alexion Pharmaceuticals Inc. 6. Gostynski M, Engelter S, Papa S, Ajdacic-Gross V, Gutzwiller F, Lyrer P. Incidence of first-ever ischemic stroke in the Canton Basle-City, Switzerland. J Neurol. 2006;253:86-91. 7. Richards SJ, Barnett D. The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory. Clin Lab Med. 2007;27:577-590. 8. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256-1264.

This site is intended for US audiences only. © Copyright and Terms of Use 1999 - 2010 Alexion Pharmaceuticals. All rights reserved. Site Map | Privacy Policy | Legal | Glossary
SOLUS03-0158-001